Estimated Projection of US Cancer Incidence and Death to 2040

Abstract

IMPORTANCECoping with the current and future burden of cancer requires an in-depth understanding of trends in cancer incidences and deaths. Estimated projections of cancer incidences and deaths will be important to guide future research funding allocations, health care planning, and health policy efforts.OBJECTIVE To estimate cancer incidences and deaths in the United States to the year 2040.DESIGN AND SETTING This cross-sectional study's estimated projection analysis used population growth projections and current population-based cancer incidence and death rates to calculate the changes in incidences and deaths to the year 2040. Cancer-specific incidences and deaths in the US were estimated for the most common cancer types. Demographic cancer-specific delay-adjusted incidence rates from the Surveillance, Epidemiology, and End Results Program were combined with US Census Bureau population growth projections (2016) and average annual percentage changes in incidence and death rates. Statistical analyses were performed from July 2020 to February 2021. MAIN OUTCOMES AND MEASURES Total cancer incidences and deaths to the year 2040.RESULTS This study estimated that the most common cancers in 2040 will be breast (364 000 cases) with melanoma (219 000 cases) becoming the second most common cancer; lung, third (208 000 cases); colorectal remaining fourth (147 000 cases); and prostate cancer dropping to the fourteenth most common cancer (66 000 cases). Lung cancer (63 000 deaths) was estimated to continue as the leading cause of cancer-related death in 2040, with pancreatic cancer (46 000 deaths) and liver and intrahepatic bile duct cancer (41 000 deaths) surpassing colorectal cancer (34 000 deaths) to become the second and third most common causes of cancer-related death, respectively. Breast cancer (30 000 deaths) was estimated to decrease to the fifth most common cause of cancer death. CONCLUSIONS AND RELEVANCEThese findings suggest that there will be marked changes in the landscape of cancer incidence and deaths by 2040.

Screening for Hepatocellular Carcinoma in Patients with Hepatitis B

“…This increase is mainly driven by external factors, such as an influx of immigration from countries with a high CHB prevalence. The increase in CHB has been paralleled by an increase in HCC, which is now the fastest growing cancer in the United States in terms of incidence [ 1 ]. Furthermore, the proportion of HCC cases resulting from CHB has also increased, with one American study demonstrating that the proportion of CHB-induced HCC cases grew from 4% to 21% [ 16 ].…”

“…Liver cancer is a leading cause of morbidity and mortality on a global scale, with approximately 30,000 deaths expected annually in the United States in 2020 [ 1 ], and significantly increased incidence rates modelled by 2030 world-wide [ 2 ]. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for approximately 75–85% of liver cancer cases [ 3 ].…”

Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma

“…With an average five-year survival of less than 10%, pancreatic ductal adenocarcinoma (PDA) is an extremely lethal malignancy [1]. The disease rate is increasing; it is estimated that PDA will rise from the third to the second leading cause of cancer-related death in the U.S. by 2025 [2]. Systemic therapies are often ineffective with high rates of intrinsic and acquired resistance to conventional treatment regimens.…”

Apoptosis in the Pancreatic Cancer Tumor Microenvironment—The Double-Edged Sword of Cancer-Associated Fibroblasts

“…Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among solid cancers with a 5-year survival of less than 9% [ 1 ], with these numbers predicated to worsen [ 2 ]. The high mortality is mainly attributed to the particularly aggressive biology of PDAC, coupled with the late presentation and diagnosis at advanced stages when curative surgery is not feasible [ 3 ].…”